Are women more susceptible than men to drug-induced QT prolongation? Concentration-QTc modelling in a phase 1 study with oral rac-sotalol

Br J Clin Pharmacol. 2014 Mar;77(3):522-31. doi: 10.1111/bcp.12201.

Abstract

Aim: To study the differences in QTc interval on ECG in response to a single oral dose of rac-sotalol in men and women.

Methods: Continuous 12-lead ECGs were recorded in 28 men and 11 women on a separate baseline day and following a single oral dose of 160 mg rac-sotalol on the following day. ECGs were extracted at prespecified time points and upsampled to 1000 Hz and analyzed manually in a central ECG laboratory on the superimposed median beat. Concentration-QTc analyses were performed using a linear mixed effects model.

Results: Rac-sotalol produced a significant reduction in heart rate in men and in women. An individual correction method (QTc I) most effectively removed the heart rate dependency of the QTc interval. Mean QTc I was 10 to 15 ms longer in women at all time points on the baseline day. Rac-sotalol significantly prolonged QTc I in both genders. The largest mean change in QTc I (ΔQTc I) was greater in females (68 ms (95% confidence interval (CI) 59, 76 ms) vs. 27 ms (95% CI 22, 32 ms) in males). Peak rac-sotalol plasma concentration was higher in women than in men (mean Cmax 1.8 μg ml(-1) (range 1.1-2.8) vs. 1.4 μg ml(-1) (range 0.9-1.9), P = 0.0009). The slope of the concentration-ΔQTc I relationship was steeper in women (30 ms per μg ml(-1) vs. 23 ms per μg ml(-1) in men; P = 0.0135).

Conclusions: The study provides evidence for a greater intrinsic sensitivity to rac-sotalol in women than in men for drug-induced delay in cardiac repolarization.

Keywords: PK/PD; QT prolongation; QT/QTc; gender; gender difference; rac-sotalol.

Publication types

  • Clinical Trial, Phase I
  • Comparative Study

MeSH terms

  • Administration, Oral
  • Adrenergic beta-Antagonists / administration & dosage
  • Adrenergic beta-Antagonists / adverse effects*
  • Adrenergic beta-Antagonists / pharmacokinetics
  • Anti-Arrhythmia Agents / administration & dosage
  • Anti-Arrhythmia Agents / adverse effects*
  • Anti-Arrhythmia Agents / pharmacokinetics
  • Drug Administration Schedule
  • Electrocardiography
  • Female
  • Heart Rate / drug effects*
  • Humans
  • Linear Models
  • Long QT Syndrome / chemically induced*
  • Long QT Syndrome / diagnosis
  • Long QT Syndrome / physiopathology
  • Male
  • Risk Assessment
  • Risk Factors
  • Sex Factors
  • Sotalol / administration & dosage
  • Sotalol / adverse effects*
  • Sotalol / pharmacokinetics

Substances

  • Adrenergic beta-Antagonists
  • Anti-Arrhythmia Agents
  • Sotalol